From the Journals

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

Share

  • 1

    Nirsevimab reduces RSV hospitalizations by 82.7%.

  • 2

    Study included 8,057 infants, aged ≤12 months.

  • 3

    75.3% efficacy against severe RSV-associated LRTI.

  • 4

    Safety data shows no new concerns; mainly Grade 1-2 events reported.

  • 5

    Effective across various age and weight categories.

  • 6

    Trial funded by Sanofi and AstraZeneca, registered as NCT

  • 7

    Provides a flexible administration schedule aligned with well-baby visits.

  • 8

    Ongoing safety follow-up for UK participants for 24 months.

Original Source(s)

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

  • by Stanley Gajete

  • July 17, 2025

  • 3 min

Related Content

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.

COVID-19 Booster in Pregnancy Linked to Higher Infant Antibodies

A COVID-19 mRNA booster given during pregnancy is associated with greater transplacental antibody transfer and sustained infant antibody levels through 6 months of age.

Rotavirus Co-Inventor Removed From FDA Vaccine Committee

Paul Offit, a longtime FDA advisor and prominent figure in vaccine development, sidelined from vaccine committee amid healthcare turmoil in the US.